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Theaimofthisstudywastocomparetreatmentwithculturedbonemarrowstromalcells(cBMSCs),bonemarrowMononucleated
Cells (BMMNCs), and placebo to repair collagenase-induced tendinitis in horses. In six adult Standardbred horses, 4000IU of
collagenase were injected in the superﬁcial digital ﬂexor tendon (SDFT). Three weeks after collagenase treatment, an average of
either 5.5 × 106 cBMSCs or 1.2 × 108 BMMNCs, ﬁbrin glue, and saline solution was injected intralesionally in random order. In
cBMSC- and BMMNCS-treated tendons, a high expression of cartilage oligomeric matrix protein (COMP) and type I collagen,
but low levels of type III collagen were revealed by immunohistochemistry, with a normal longitudinally oriented ﬁber pattern.
Placebo-treated tendons expressed very low quantities of COMP and type I collagen but large numbers of randomly oriented type
IIIcollagenﬁbers.BothcBMSCandBMMNCSgraftsresultedinaqualitativelysimilarhelingimprovementoftendonextracellular
matrix, in terms of the type I/III collagen ratio, ﬁber orientation, and COMP expression.
1.Introduction
The use of autologous mesenchymal cells from BM to
repair experimental injuries of tendons and ligaments has
been amply described in experimental animals [1, 2]. In
2003, Smith et al. [3] were the ﬁrst to suggest the use
of autologous BM mesenchymal cells to treat spontaneous
tendon lesions in horses [4–6]. Despite these very promising
results,onlyclinicalandultrasonographicexaminationshave
been evaluated.
The delivery of Bone marrow mononucleated cells
(BMMNCs) has been described as an alternative procedure
to grafting MSCs in injured tissues. Their successful use has
been reported in the treatment of myocardial infarct lesions,
bone defect reconstruction, and ischemia-reperfusion mus-
cle injury [7–13]. The idea of using BMMNCS autografts
is based on the assumption that among the mononucleated
cells MSCs, which are present in only relatively small
numbers in BM aspirates, can be easily separated ex-vivo
(i.e., in the laboratory) from the rest of the harvested
cells, concentrated in small volumes, and then immediately
implanted into the patient’s injured tissue.
The aim of this study was to compare tendon healing
following transplantation of cultured bone marrow stromal
cells (cBMSCs), bone marrow mononucleated cells (BMM-
NCS), and placebo in an equine model of collagenase-
induced tendinitis.
2.MaterialsandMethods
2.1. Horses. The study was performed at the School of Vet-
erinary Medicine, University of Bari, after having obtained2 Veterinary Medicine International
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Figure 1: Time course description of the study performed over a
period of 24 weeks (T-3-T21); US data were recorded immediately
prior to collagenase injection to induce tendon injury, recorded as
T-3, then 3 weeks later, just prior to injection of either cBMSC or
BMMNCS suspension, ﬁbrin glue, or placebo (= saline) into the
tendonlesion(T0),andagainat3,6,8,12,16,18,and21weeks(T3-
T21) following tendon treatment. At T21, animals were euthanized
and the SDFTs of all four limbs were harvested and processed for
histology and immunohistochemistry examination.
approvalfromtheMinisteryofHealth,Rome,Italy(approval
4/2005 and executed under Animal care guidelines). Six
stallions Standardbred horses, aged 4 years and with a mean
weight of 522 ± 30kg, not suﬀering from previous tendon
injury, were used in this investigation following 4 weeks of
stall rest prior to beginning the study.
2.2. Time Course Description. T h et i m ec o u r s eo ft h ee x p e r i -
ments is depicted in Figure 1.
2.3. Collagenase-Induced Tendinitis Model. Four horses
received collagenase in all legs, while the other two only in
three legs (left fore, right fore, and right hind—the left hind
limb was not injected and served as a sham control). 4000IU
of Clostridium histolyticum Type 1A collagenase (Sigma,
Milan, Italy) were injected under ultrasonographic guidance
intozone2B(14cmdistaltotheaccessorycarpalbone;21cm
distal to the tuber calcanei) of each superﬁcial digital ﬂexor
tendon (SDFT). Buprenorphine (6µg/kg intravenously [IV])
was administered as analgesic twice a day for 7 days.
After 3 weeks, the lesions were clinically and ultrasono-
graphically evaluated. After 21 weeks, the animals were
euthanized and the SDFTs of all four limbs were harvested
and processed for histology and immunohistochemistry
examinations.
2.4. Bone Marrow Collection. For BM aspiration, the horses
were sedated with detomidine (20µg/kgIV) and butor-
phanol (10µg/kgIV) and restrained in a standing stock.
BM was harvested on two occasions from the horses’
tuber coxae, using an 8G Jamshidi needle and heparinized
50mL-syringes. An average of 35mL was collected on
the same day of collagenase injection (T-3) for cBMSC
c u l t u r e sa n da na v e r a g e4 6 m Lo nd a y2 1( T 0 )f o rp r o -
cessing BMMNCS, harvested from the tuber coxae on the
opposite site. Buprenorphine was administered (2µg/kg)
but no other analgesics or antiinﬂammatory drugs. The
BM aspirate was immediately transported to the on-site
laboratory.
2.5. BMMNCS. The BM was diluted 1 : 1 in PBS, then
stratiﬁed 1 : 1 on Biocoll Separating solution (FICOLL,
gradient 1.077g/mL, Biochrom, Leonopenstr 2–6, D-12247,
and Berlin, Germany) and centrifuged at 2000rpm × 30
minutes. The separated cells were counted using nuclear
staining (0.1% methyl violet in 0.1M citric acid). The cells
were rinsed twice with phosphate buﬀer solution (PBS)
and then suspended in an adequate amount of ﬁbrin
glue (Tissucol, Baxter Spa, Rome, Italy) depending on the
extent of the SDFT lesion (calculated ultrasonographically)
where they were to be injected. To evaluate the capacity of
the cells to form colony-forming unit ﬁbroblasts (CFU-f),
100µL of cells were seeded before and after density gradient
centrifugation in two Petri dishes measuring 100mm in
diameter in complete medium (Coon’s F 12 medium, 10%
FBS,100IU/mL penicillinand streptomycin,5% ofa 200µM
solution of L-glutamine (Biochrom, Leonopenstr 2–6, D-
12247, Berlin, Germany)), and incubated at 37
◦Ci nah u m i d
5% CO2/air (carbogen) atmosphere for two weeks, replacing
the medium twice a week. The cells were then washed
with PBS, pH 7.2, ﬁxed with buﬀered formalin 4% and
stainedwith1%methyleneblueinboratebuﬀer(10mM,pH
8.8).
Approximately 2h after BM collection, density gradient
centrifugation of native BM aspirates yielded 122.3 ± 23.1 ×
106 BMMNCs that were suspended in a mean volume of
2.0 ± 0.5mL of ﬁbrin glue for subsequent injection into
tendon lesions.
2.6. Culture of BMSCs. To obtain cBMSCs from harvested
BM, the mononuclear bone marrow cells were isolated
by density gradient centrifugation as described above for
BMMNCS and were seeded in ﬂasks at a concentration of
4-5×106 cells/cm2 in complete medium (Coon’s, Biochrom,
Leonopenstr 2–6, D-12247, Berlin, Germany) at 37
◦Ci na
humid 5% CO2/air (carbogen) atmosphere. The medium
was replaced twice a week until the cells became conﬂuent.
Cells were harvested from dishes at the ﬁrst passage, that
is, after 3 weeks of cultivation. The BMSCs cultures were
trypsin-treated in a routine manner and, after collection
in Falcon tubes, the detached cells were rinsed in PBS and
centrifuged twice at 1200rpm for 10 minutes. A subsequent
cell count revealed an average 5.5 × 106 cells, which were
s u s p e n d e di nam e a no f4 .2 ± 2.3mL of ﬁbrin glue for
transplantation into the tendon.
2.7. cBMSC, BMMNCS, and Placebo Injection. On the day of
cell transplantation (T0, 3 weeks after collagenase injection),
horses were sedated as described before for BM collection
and under local skin block with 1mL lidocaine 2%, a 23G
needle was inserted laterally into the tendon lesion using
transverse US scans for guidance. Volume of ﬁbrin, cells
suspension, or saline had been considered on the basis of
approximately lesion size calculated by US evaluation of
CSA-l (mm2) × length of the lesion (mm). Subsequently,
either cBMSC or BMMNCS suspension, ﬁbrin glue or saline
was randomly assigned to each leg and injected by US-
guidance to ﬁll the defect in the tendon. Immediately afterVeterinary Medicine International 3
injection into the lesion, a small amount of thrombin
(0.5mL,500IU/mL;BaxterBioscience,Pisa,Italy)wasadded
to clot the suspension.
2.8. Ultrasound Examination. Ultrasound examinations
were performed with GE LS-400 equipped with an 11MHz
linear probe prior to collagenase injection (T-3) and at 0
(the day of cell graft treatment), 3, 6, 8, 12, 16, 18, and 21
weeks (T0-T21) following tendon treatment. The following
parametersweredeterminedtoquantifythedegreeandtime-
related changes of the SDFT lesion: tendon echogenicity
score(TES),ﬁberpatternscore(FPS),andthecross-sectional
area percentage of the lesion (% CSA-l) assessed in the zone
of maximum injury (MIZ), as well as the length of tendon
lesion (in mm) measured in longitudinal US images. For
semiquantitative TES evaluation, scores were assigned as 0
(isoechoic), 1 (hypoechoic), 2 (extremely), and 3 (anechoic)
(Genovese and Rantanen [14]). The FPS describes the
alignment of collagen ﬁbers in longitudinal scans, with low
values indicating a normal longitudinal ﬁber pattern and
higher scores describing a greater degree of nonlongitudinal
ﬁber pattern, that is, disrupted pattern: 0 (>75%), 1 (50%–
74%), 2 (25%–49%), 3 (<25%) (Genovese and Rantanen,
1998). The % CSA-l refers to the ratio between the lesion
cross section and the entire cross- sectional area of the SDFT.
2.9. Histology. Histological and immunohistochemical eval-
uation has been performed in blinded fashion by a single
operator. Starting from the maximum injury zone MIZ,
SDFTs were divided into 1cm sections on either side of the
maximum injury zone, obtaining a total of 8 blocks from
each harvested tendon. Each block was ﬁxed in 10% neutral
buﬀered formalin, and, after 48h, sections of 1.5mm thick-
ness in the longitudinal direction (frontal plane) were placed
in a transilluminator for gross morphological evaluation
(i.e., areas of maximum injury and disorganization of peri-
tendon structures) and digital photographs were recorded;
then tendons were furthermore sectioned according to the
longitudinal axis, following the orientation of the collagen
ﬁbers arrangement and sections were paraﬃne m b e d d e d .
Three µm thick sections were obtained and stained with
hematoxylin-eosin (HE) stain for histopathological exami-
nation and with Herovyci’s polychrome stain for precollagen
and collagen diﬀerentiation (Busoni et al. [15]). Histological
examination of SDFT portions included assessment of areas
of alignment of collagen ﬁbers in a longitudinal pattern,
using a ﬁber orientation score (FOS). Unlike the US
examinations (FPS score),highFOS values indicate anormal
longitudinal ﬁber pattern, while lower scores describe a
greater degree of nonlongitudinal or disrupted pattern: 0
(>75%), 1 (50%–75%), 2 (25%–49%), 3 (<25%), where
the percentages refer to the ratio of damaged area to the
entire cross-sectional area of the SDFT, as assessed at a
magniﬁcation of 10×. For each considered parameter (i.e.,
predominant percentage of aligned or unaligned-cross or
ﬁngerprint pattern organized ﬁbers), ﬁve randomly selected
ﬁeldswereobserved,andthescorewasevaluatedasthemean
percentage of the examined ﬁelds.
The number of mononuclear inﬂammatory cells such as
lymphocytes, plasma cells, and macrophages was assessed
at 40× magniﬁcation (high-power ﬁeld—HPF). For this
evaluation, ten randomly selected ﬁelds were examined
per each tendon sample. The number of these cells was
recorded and results were reported as the mean value for
the entire specimen, and then the degree of mononucleated
inﬂammatory cell inﬁltration (MICI) was scored. Number
of inﬂammatory mononuclear cells was considered to be
normal when none or only a few cells were seen in each
HPF among collagen ﬁbers (score 0). Increase in number
of cells was considered mild for specimens with several cells
per HPF (score 1), moderate (score 2) for specimens with
many cells for HPF, or marked (score 3) for specimens
with numerous to very numerous cells per HPF, respectively.
Histological criteria for a normal tendon structure included
detection of a perfect alignment in a parallel manner
of collagen ﬁbers, and the absence of inﬂammatory cells
between ﬁbers and a homogeneous character of mature
collagen, revealed by intense red staining of ﬁbers using the
Herovyci method.
2.10. Immunohistochemistry. To evaluate the type of col-
lagen synthesized in damaged and normal areas and to
immunohistochemically characterize the cell populations
inﬁltrating the tendons, the following polyclonal antibodies
(pAbs) were used in serial sections: rabbit pAb anti-collagen
type I (Chemicon, Temecula, CA), rabbit pAb anti-collagen
type III (Chemicon, Temecula, CA), rabbit pAb anti-
cartilage oligomeric matrix protein (COMP; Abcam, Cam-
bridge, UK), mouse mAb anti-vimentin (Dako, Glostrup,
Denmark), and mouse mAb anti-CD34 (Clone BL-35C,
Zymed Inc., San Francisco, CA). Speciﬁc primary antibodies
substituted with TBS or nonimmune sera were used as
negative controls in immunohistochemical techniques.
For immunohistochemistry tests, sections were placed
on pretreated slides (Bio-Optica, Milan, Italy) to promote
adhesion and dried overnight at 37
◦C. After dewaxing, sec-
tions were placed in EDTA buﬀer, pH 9.0, and processed in a
microwaveovenat650Wfortwocyclesof10minuteseachto
enhancetheirantigenicity.Slideswerethenallowedtocoolat
room temperature for at least 20 minutes before further pro-
cessing for immunostaining employing standard procedures.
Tissue sections were incubated overnight in a moist chamber
at 4◦Cw i t hd i ﬀerent primary antibodies, diluted 1 : 50
in Tris-buﬀered solution (TBS) containing 0.1% crystalline
bovine serum albumin (BSA). Binding of the antibodies
wasdetectedwithABC-peroxidase(VectorLaboratoriesInc.,
Burlingame, CA) techniques using 1 : 200 diluted biotin
conjugated goat anti-rabbit immunoglobulin G (Vector
Laboratories Incorporated, Burlingame, CA) and a 1 :
200 diluted biotinylated goat anti-mouse immunoglobulin
(AO433;DAKO,Glostrup,Denmark),appliedfor45minutes
atroomtemperatureassecondaryantibodies.Theenzymatic
reaction was developed with 3, 1-diaminobenzydine (DAB)
(Sigma, St. Louis, MO) or VIP (Vector), as substrate for
the ABC-peroxidase technique, using Meyer hematoxylin as
nuclear counterstain.4 Veterinary Medicine International
Immunohistochemical evaluation was made of collagen
type I or III prevalent expression in damaged and nor-
mal areas of tendon tissue, of cartilage oligomeric matrix
protein (COMP) expression, and the presence of CD34
positive staining (CD34+) mononuclear cells interspersed
or localized in perivascular fashion throughout the dam-
aged area of the SDFT, assessed at 100×. A score of
0 (absence of antigen expression), 1 (weak and spotted
antigen expression), 2 (weak but diﬀuse antigen expression
throughout the entire specimen), and 3 (diﬀuse and strong
antigen expression) was assigned to the semiquantitative
evaluation of the immunohistochemical reaction to each
antigen employed.
2.11.StatisticalAnalysis. Numerical data are given as mean±
SD. Two-way ANOVA (repeated measure analysis) analysis
wasconductedtotestthetreatmentbytimeinteractions,and
the eﬀect of treatment over time. If an interaction of time
by time was detected at the 0.05 level of signiﬁcance, then a
subgroup analysis was made of the eﬀect of treatment at each
time point at the 0.05 level, using a least square diﬀerence
(LSD) test as post-hoc test.
Evaluation of histological and immunohistochemical
scores was conducted by U-Test (Mann-Whitney) to com-
pare treatments (signiﬁcance P ≤ .05).
3. Results
3.1. Colony Forming Units of Fibroblasts (CFU-f) Count. The
numberofculturedish-adherentBMstemcellsthatcanform
a colony was quantiﬁed as CFU-f. Prior to Ficoll gradient
centrifugation, the original BM aspirate in all 6 horses
consisted of a mean of 428 ± 223 CFU-f per mL (pre-Ficoll)
while postcentrifugation (post-Ficoll) the number rose to
1697 ±785 CFU-f per mL.
3.2. Ultrasonographic Findings
3.2.1. Tendon Structure before and after Collagenase-Induced
Tissue Injury. Ultrasound examination at the beginning of
the study (T-3) was made to check for an intact tendon
structure of the SDFT in all 4 limbs, with no evidence
of previous injury. Three weeks after collagenase injection,
(T0) US examination conﬁrmed signiﬁcant SDFT lesions,
which were not uniform in shape and length. Nevertheless,
T E Sa n dF P Ss c o r e s ,%C S A - l ,a n dl e n g t ho fl e s i o na tT 0
were not diﬀerent among limbs or horses (P>. 05). The
experimentally induced lesions in all 22 SDFTs were on
average 38.8 ± 10.4mm long, with a lesion CSA to tendon
CSA ratio of 30.1 ± 11.6% at the MIZ. At T0, TES, and FPS
scores were 2.9 ±0.3a n d2 .9 ±0.3, respectively.
3.2.2. Tendon Structure following Treatment. Between T3 and
T6, SDFT lesions were still well appreciable in US images
although a progressive improvement in the TES and FPS
scores as well as the % CSA-l was noted, but without any
signiﬁcant diﬀerence among diﬀerently treated tendons.
At T8, US determination of % CSA-l revealed no
statistical diﬀerence between tendons treated with cBMSCs
or BMMNCS, whereas the % CSA-1 was signiﬁcantly larger
in saline and ﬁbrin-injected SDFTs (P<. 05). At this time
point, TES and FPS scores were still diﬀerent from baseline
(T-3) values, but had signiﬁcantly improved as compared
to the examination at T0 (P<. 05). From T16 on up to
T21, the TES, FPS, and % CSA-l values in cBMSC- and
BMMNCS-injected SDFTs were signiﬁcantly diﬀerent from
those measured in ﬁbrin and placebo-treated SDFTs (P<
.05). US scans are depicted in Figure 2.
3.3. Histology Findings. Representative histological slides in
the experimental horses are shown in Figures 3 and 4.
Scores describing the changes in morphological (ﬁber
orientationandmononuclearcellsinﬁltrationinSDFTs)and
immunohistochemical parameters (degree and intensity of
collagenI/III,COMP,andCD34expression)aresummarized
in Table 1.
3.4. Immunohistochemistry Findings. Immunohistochemical
stains for type I and III collagen revealed a high expression of
type I collagen in cBMSC- and BMMNCS-injected tendons,
but very low expression of type III collagen(Figures 3 and 4).
Scores describing the changes in immunohistochemical
parameters (degree and intensity of collagen I/III, COMP
and CD34 expression) are summarized in Table 1.
4. Discussion
The present results provide evidence that regeneration of
injured tendon tissue can be achieved in the horse with
intralesionalinjectionofbothcBMSCsandBMMNCS,while
placebo (saline or ﬁbrin) injection leads to scar tissue repair
of the damaged site. Collagen expression was equally well
restored in both cell graft groups, with type I collagen
ﬁbers largely predominating over type III collagen ﬁbers.
Interestingly, our study conﬁrms that COMP, an abundant
noncollagenous pentameric glycoprotein in the tendon [16],
is well expressed in normal equine SDFTs, and the level of
expression is strictly related to a high percentage of physio-
logically oriented collagen type I ﬁbers. Similar results were
observed in both cBMSC- and BMMNCS-injected tendons
but not in placebo controls. Previous studies demonstrated
the ultrastructural distribution of COMP and its correlation
to collagen ﬁber thickness in diﬀerent compartments of
equine ﬂexor tendons, with a particular concentration of this
protein at the gap region of collagen type I and II ﬁbers [17].
ThestructureandorganizationoftheECM,andinparticular
the axial alignment of type I collagen ﬁbers, are essential for
the tensile strength of tendons and are mainly related to the
COMP presence and distribution [17].
Type I collagen ﬁbers were longitudinally oriented in
cell-graft injected tendons, indicating a physiological texture
of the repaired tissue sites. Following both cBMSC and
BMMNCS treatments, the tendon ECM did not diﬀer in
terms of the type I/III collagen ratio and ﬁber orientationVeterinary Medicine International 5
Table 1: Morphological and immunohistochemical scores evaluated for each horse at 21 weeks following treatment of collagenase-induced
tendinitis SDFT, superﬁcial digital ﬂexor tendon; RH, right hind limb; LF, left fore limb; RF, right fore limb; cBMSCs, cultured bone marrow
mesenchymal cells; BMMNCS, bone marrow mononucleated cells; FOS, ﬁber orientation score; MCI, mononucleated cell inﬁltration score;
Collagen I, type I collagen ﬁber expression score; Collagen III, type III collagen ﬁber expression score; COMP, cartilage oligomeric matrix
protein expression score; CD34, score describing presence of CD34+ mononuclear cells localized throughout the damaged area of the SDFT
(see Section 2 for more details). Signiﬁcant diﬀerences from placebo group: #P<. 05.
Treatment Histological and immunohistochemical scores
FOS MCI Collagen I Collagen III COMP CD34
cBMSCs 3.0 1.6 2.6 1.2 2.2 1.0
sd 0.0 0.5 0.5 0.4 0.4 0.7
BMMNCS 3.0 2.4 3.0 1.4 2.4 2.0
sd 0.0 0.5 0.0 0.5 0.5 0.7
Fibrin 0.5 0.5 1.0 3.0 0.5 0.0
sd 0.7 0.7 0.0 0.0 0.7 0.0
Placebo 0.8 0.5 1.3 2.3 1.3 0.0
sd 1.0 0.6 0.5 0.5 0.5 0.0
T0 T21
CE
cBMSC
BMMNC
Fibrin
Saline
Figure 2: Longitudinal and transverse ultrasound images recorded on T0, that is, the day of injection of intralesional cultured bone marrow
mesenchymal cells (cBMSC), bone marrow Mononucleated Cells (BMMNCS), ﬁbrin and saline, and at T21, 21 weeks after treatment.
from intact SDFT tissue (tendons in sham controls). By con-
trast, in placebo-treated lesions type III collagen formation
predominated while type I collagen was only marginally
expressed and the ﬁbers were randomly oriented, indicating
the loss of a normal tissue structure. As to the presence of
some immature collagen in both cBMSC- and BMMNCS-
treated tendons, we can only speculate that the ﬁnding could
be due to minimal mechanical tendon load as a result of
prolonged stall rest.
BMMNCs are characterized by CD34+ surface marker
while BMSC express the surface marker CD34+ during
an early phase but lose it in adult cells [18]. Thus the
presence of cells that express the marker CD34+ in treated
tendons is the evidence of a chemotactic eﬀect promoted by
the MSCs. Additionally, in our opinion, the presence of a
certain percentage of CD34+ mononuclear cells localized in
perivascular areas of the interfascicular zone of BMMNCs-
treatedSDFTspointedtowardthepossibleangiogenicroleby6 Veterinary Medicine International
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Figure 3: Tissue slides obtained from SDFTs injected with cBMSCs, and BMMNCS. Tissue stains with hematoxylin-eosin (H and E) and
Herovyci (Hero) highlight the longitudinal orientation of collagen ﬁbers after transplantation of cBMSCs and BMMNCS; Histological
examination of the sham tendons, both with HE and Herovyci staining, showed the presence of mature collagen (i.e., predominantly strong
redHerovycistainingofﬁbersintendonsections)andalongitudinalﬁberorientation,signifyinganormaltendonarchitecture.Additionally,
the absence or very scanty mononuclear cell inﬁltrate was observed in all normal control tendons. No inﬂammatory or other reactions to
the ﬁbrin glue were observed in any of the treated limbs, and at T21 no ﬁbrin residues were recognized in microscopic examinations.
(T21) Tissue slides from the superﬁcial digital ﬂexor tendons (SDFT) following experimentally induced tissue injury and subsequent
treatment with cultured bone marrow mesenchymal stem cells (cBMSCs (a)) and Bone Marrow Mononucleated Cells (BMMNCS (b)).
Incomplete maturation of collagen was veriﬁed by the observation of blue staining ﬁbers mixed with red ones. In BMMNCS a large
number of mononucleated cells are recognizable in the interfascicular zone. Immunohistochemistry stains for Collagen type I (C/I) and
collagen type III (C/III) show a high expression of C/I and a very low expression of C/III. Stains for cartilage oligomeric matrix protein
(COMP) expression. BMMNCS-treated SDFT (b) show a strong, diﬀuse expression like sham SDFT (Figure 4(c)). Immunohistochemistry
staining for the expression of CD34+ mononucleated cells in cBMSCs (a) shows a low expression limited to the interfascicular zone. In
BMMNCS(b)-treatedSDFT,thepresenceofnumerousmononucleatedCD34+cellsnearmicrovessels,whichsometimesshowsomeCD34+
endotheliocytes in their wall, which is highlighted. In cBMSC- and BMMNCS-treated SDFTs, microscopic examination at T21 revealed a
longitudinal orientation of newly formed collagen ﬁbers. At this time point, sections stained by the Herovyci method revealed minimal
areas of blue-stained thin, well-oriented precollagen ﬁbers mixed with well-diﬀerentiated and- oriented red-stained mature collagen ﬁbers,
indicating a still somewhat incomplete collagen maturation at this time in the treatment. In BMMNCS-treated SDFTs also, large numbers
of mononucleated cells were present in the interfascicular zone. In contrast, in placebo SDFTs, injected with saline or ﬁbrin, the tissue
architecture was disrupted or markedly modiﬁed, showing blue precollagen and red collagen ﬁbers randomly or not longitudinally oriented,
and a relatively loss of the architectural pattern.
endothelial diﬀerentiation of these cells. Thus, the presence
of cells expressing CD34+ in tendons provides evidence
that cBMSCs and BMMNCS home into the tendon after
treatment, and presumably they have an attractive eﬀect
for local CD34+ cells into the treated lesion. Additionally,
in our opinion, the presence of a certain percentage of
CD34+ mononuclear cells localized in perivascular areas of
theinterfascicularzoneofBMMNC-treatedSDFTssuggested
the presence of surviving clones of injected cells and, in
relation to their location, a possible angiogenic role of these
cells by endothelial diﬀerentiation.
The value of cBMSCs in the treatment of lesions in bone,
skeletal and cardiac muscle, and other mesenchymal tissues
has already been demonstrated [1, 2]. This also applies to
equine tendon injuries and was described in a study of 235
horses treated with autologous cultured mesenchymal cell
grafts[3].However,theapplicationofthistechniquerequires
a fairly sophisticated cell culture laboratory and highly
qualiﬁed personnel, both of which are often not accessible
toclinicians and/orarecost-prohibitive forveterinarians and
animal owners. In addition, atleast3-4 weeks elapse between
BM collection and the time of cBMSC transplantation into
the tendon lesion, a delay that may have a negative impact
on the quality and speed of tissue healing. It has been
demonstrated that extensive in-vitro proliferation seems to
aﬀect both the replication potential of BM-derived MSCs
and their diﬀerentiation capacity [19–23]. In fact, after the
ﬁrst conﬂuence, the proliferation rate of cultured BM stem
cells slows down; as a result of in-vitro expansion, the bone-
forming activity of BM stem cells in vivo is dramatically
decreased as compared to fresh BM stem cells and their in-
vitro multidiﬀerentiation potential which is gradually lost
[19, 23]. This loss of in-vivo diﬀerentiation potential after
in-vitro expansion drastically limits the potential use of BM-
derived stem cells for therapeutic purposes [22].
Although in the present study both cBMSC and BMM-
NCS injections produced an equally good regeneration of
tendon tissue in terms of the quality of Collagen I/III
ratio expression and architecture and COMP, BMMNCS
transplantation is a simpler as well as a more time- and cost-
eﬀective procedure than cBMSC therapy. The separation of
BMMNCs from BM aspirate (BMMNCS) makes it possible
to obtain a large number of MSCs in a short period of time
(only 2h from BM harvesting) by employing only a one-
step technique (Ficoll gradient centrifugation) without the
needforcellculture.The BMMNCS-basedgraftscanthenbe
concentrated in the small injected volume needed to ﬁll the
tissue lesion. To transplant the same number of MSCs using
native BM aspirate, a much larger volume has to be injected
into the tendon, that could create an iatrogenic tendinitis of8 Veterinary Medicine International
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Figure 4: (T21) Tissue slides from the superﬁcial digital ﬂexor tendons (SDFT) following experimentally induced tissue injury and
subsequent treatment with Fibrin (c), Saline (d), and normal tendon (e). Tissue stains with hematoxylin-eosin (H and E) and Herovyci
(Hero)showlossofthelongitudinalﬁberpatternandcrimpintendonstreatedwith-Fibrin(c);inSalinetreatedtendon(d),thereiscomplete
disruption with randomly oriented ﬁbers, clearly shown in the central area. The collagen I/III ratio in Fibrin treated tendon (c) is clearly
lower than in normal (e) and cell grafted tendon (Figures 3(a) and 3(b)); in Saline (d) treated tendon, the central zone was highly positive
for collagen type III but not for type I. Stains for cartilage oligomeric matrix protein (COMP) show stack and spread expression in both
control-treated SDFT (c-d). In immunohistochemistry staining for the expression of CD34+ mononucleated cells in Fibrin (c), Saline (d)
and Normal (e) Tendon, only sporadic CD34+ stained mononuclear elements were detected. By contrast, in all three placebo-treated SDFTs,
the location of the lesion was readily identiﬁed as an area with high positivity for type III collagen, very low expression of type I collagen and
in some zones, evidence of mineralization. Similarly to the trend of type I collagen expression, COMP was expressed in a homogeneous and
diﬀuse pattern in sham untreated control SDFTs as well as in cBMSC- and BMMNCS-injected tendons. Scant, weak expression of COMP,
restricted to areas that circumscribed the injected portions of the tendon, was observed in all three placebo-treated SDFTs. As expected, no
CD34+ mononuclear cells were observed in the sham tendon sections. Similar results were obtained in sections of placebo-injected SDFTs,
although a certain number of inﬂammatory cells were present, interspersed in perivascular areas of these tendons (data not shown). Only
sporadic CD34+ stained mononuclear elements (i.e., 0 to 2 per HPF) were observed in cBMSC-injected tendons (data not shown). On the
contrary,inBMMNCS-treatedSDFTslargenumbersofmononucleatedcells,inpartCD34+stained,werepresentintheinterfascicularzone.
normal tendon tissue, and other possible complications such
as ossiﬁcation and the delivery of exogenous tissue (i.e., bone
spiculae, fat, etc.). Once transplanted into the lesion site, the
ability of MSCs included in BMMNCS to immediately clone
and diﬀerentiate into tendon tissue, forming ﬁbroblasts,
helps to avoid the signiﬁcant time delay in therapy associated
with the use of cBMSCs and thus may oﬀer the advantage of
a more rapid tissue healing and a sooner return of tendon-
injured horses to athletic performance level.
However, the caveat of having enrolled only a small
number of horses in this initial investigation and the
potential disadvantage of having studied the eﬀects of MSC
transplantation in an experimental model of tendon injury
maylimittheimplicationsofourﬁndingsforclinicalpractice
andcallsforamorecontrolled(ideallyblinded)experimental
study and a subsequent clinical follow-up study in a larger
number of horses.
In conclusion, this study is the ﬁrst to describe the
eﬃcacy of BMMNC injection in an equine model of
experimental tendinitis. The use of BMMNCS oﬀers sig-
niﬁcant advantages in terms of the progress and quality of
tendon healing when compared to native BM implantation.
Although both cBMSC and BMMNCS injections produced a
comparablypositiveeﬀectsontheregenerationoftendontis-
sueparticularlyintermsofthecollagenI/IIIratioandCOMP
expression, the use of BMMNCS is a simpler and more cost-
eﬀective method than the use of cultured BMSCs, and thus
its introduction into equine clinical practice may well have a
signiﬁcant impact on tendon injury treatment in the future.
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